Get the Stockscreener App
30.50
2.96%
-0.93
After Hours:
30.06
-0.44
-1.44%
Sensei Biotherapeutics Inc stock is traded at $30.50, with a volume of 113.04K.
It is down -2.96% in the last 24 hours and up +242.70% over the past month.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
See More
Previous Close:
$31.43
Open:
$30.5
24h Volume:
113.04K
Relative Volume:
0.39
Market Cap:
$38.48M
Revenue:
-
Net Income/Loss:
$-29.80M
P/E Ratio:
-25.63
EPS:
-1.19
Net Cash Flow:
$-25.19M
1W Performance:
+0.93%
1M Performance:
+242.70%
6M Performance:
+266.59%
1Y Performance:
+242.70%
1-Day Range:
$30.13
$31.30
1-Week Range:
$26.09
$32.95
52-Week Range:
$5.00
$36.76
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
30.50 | 39.65M | 0 | -29.80M | -25.19M | -1.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Fed Meeting: Whats next for CRWD stock2025 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
Trails Edge Capital Partners, LP Acquires Shares in Sensei Bioth - GuruFocus
Revenue Check: Is Sensei Biotherapeutics Inc being accumulated by smart moneyWeekly Gains Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Sensei Biotherapeutics grants stock options to 17 new employees - Investing.com
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2026 - BioSpace
Sensei Biotherapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
SNSE (NASDAQ: SNSE) insider schedules sale of 3,374 shares; prior sale 42,594 - Stock Titan
SNSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sensei Biotherapeutics Acquires Faeth Therapeutics and Raises US$200 Million in Private Placement - Global Legal Chronicle
Sensei Biotherapeutics Merges with Faeth Therapeutics, Secures $200M Funding - National Today
What is Sensei Biotherapeutics Inc. s revenue forecastJuly 2025 Trade Ideas & Precise Buy Zone Tips - mfd.ru
Sensei Biotherapeutics, Inc. (SNSE) Faeth Therapeutics, Inc.M&A CallSlideshow (NASDAQ:SNSE) 2026-02-20 - Seeking Alpha
Sensei Biotherapeutics (SNSE) COO and director added as SEC insider - Stock Titan
Sensei Biotherapeutics Acquires Faeth Therapeutics - Global Legal Chronicle
Sensei Biotherapeutics Closes Faeth Acquisition and Financing - The Globe and Mail
Sensei Biotherapeutics Secures Future with Faeth Therapeutics Acquisition and $200M Financing - Beijing Times
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - MSN
Sensei Biotherapeutics Acquires Faeth Therapeutics and Secures $200 Million Funding - El-Balad.com
Sensei Biotherapeutics PIPE in Connection with its Acquisition of Faeth Therapeutics - Leerink Partners
Sensei/Faeth Merger Will Keep Both Firms’ Cancer Pipelines Active - Citeline News & Insights
Merger deal renews Faeth in Sensei; Piktor brightens, stock jumps - BioWorld MedTech
Small Cap Stocks To Add to Your WatchlistFebruary 18th - MarketBeat
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal - Bitget
Why Is Sensei Biotherapeutics Stock Skyrocketing Wednesday?Sensei Biotherapeutics (NASDAQ:SNSE) - Benzinga
Sensei Biotherapeutics (SNSE) Shares Soar After $200M Acquisitio - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance - HIT Consultant
Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug - Fierce Biotech
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider
Sensei Jumps 150% On Faeth Therapeutics Buyout And $200M Financing - Nasdaq
Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition By Investing.com - Investing.com Canada
Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition - Investing.com
SNSE: Acquisition and $200M financing position the combined entity as a leader in multi-node cancer therapies - TradingView
Sensei Biotherapeutics (SNSE) Acquires Faeth Therapeutics to Exp - GuruFocus
SNSE: Acquisition and $200M financing advance a novel cancer therapy toward key clinical milestones - TradingView
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - The Joplin Globe
[Form 3] Sensei Biotherapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
SNSE Technical Analysis & ETF Price Forecast - Intellectia AI
Sensei Biotherapeutics Expands Board, Adds Finance Expertise - The Globe and Mail
What is the Moat Score of Sensei Biotherapeutics Inc.Earnings Risk Summary & Weekly High Return Stock Forecasts - mfd.ru
Sensei Biotherapeutics Charts a Strategic Pivot After Halting Lead Candidate - AD HOC NEWS
Is Sensei Biotherapeutics Inc. stock a top performer YTDJuly 2025 WrapUp & Free Expert Approved Momentum Trade Ideas - mfd.ru
Is Sensei Biotherapeutics Inc.’s growth already priced inPortfolio Gains Report & Community Verified Swing Trade Signals - mfd.ru
Can Sensei Biotherapeutics Inc. be the next market leaderJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
What is Sensei Biotherapeutics Incs TAM Total Addressable MarketDay Trade & Scalable Portfolio Growth Methods - baoquankhu1.vn
Market Rankings: Is Sensei Biotherapeutics Inc. a speculative investmentTrade Entry Report & Low Risk Investment Opportunities - baoquankhu1.vn
AI Stocks: What is Sensei Biotherapeutics Incs revenue forecastProfit Target & Safe Capital Allocation Plans - baoquankhu1.vn
Sensei Biotherapeutics Halts Flagship Program, Weighs Sale or Shutdown - AD HOC NEWS
Portfolio Recap: Does Sensei Biotherapeutics Inc have pricing powerDay Trade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Valuation Update: Will FG Merger II Corp Equity Right outperform its industry peersNew Guidance & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Treasury Yields: Will Sensei Biotherapeutics Inc benefit from rising consumer demandMarket Volume Summary & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):